DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Conditions
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Lin Shen, M.D.)Contact: Principal Investigator (Lin Shen, M.D)The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Contact: Study coordinator (Feng Ye, M.D)Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Contact: Study coordinator (Yanqiao Zhang, M.D)The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Contact: Study coordinator (Yanru Qin, M.D)Hubei Cancer Hospital, Wuhan, Hubei, China
Contact: Study coordinator (Huiting Xu, M.D)Hunan Cancer Hospital, Changsha, Hunan, China
Contact: Study coordinator (Zhenyang Liu, M.D)Xuzhou Central Hospital, Xuzhou, Jiangsu, China
Contact: Study coordinator (Yuan Yuan, M.D)Shandong Cancer Hospital, Jinan, Shandong, China
Contact: Study coordinator (Changzheng Li, M.D)Contact: Principal Investigator (Changzheng Li)The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Contact: Study coordinator (Jing Lv, M.D)Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Jun Zhang, M.D)West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Hongfeng Gou, M.D)Yunnan Cancer Hospital, Kunming, Yunnan, China
Contact: Study coordinator (Lin Xie, M.D)
Study leads
Jianmin Fang, Ph.D
Study Director
RemeGen Co., Ltd.